News
Please, enter cell line, author or any other phrase or word you would like to search for.
Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ)
The shareholders of Phase Holographic Imaging PHI AB (publ), reg.no. 556542-7811, are hereby invited to attend the annual general meeting on 16 October 2025 at 3 p.m. at the company´s office at Skiffervägen 48 in Lund.
PHI provides an update regarding the development progress of the new generation of HoloMonitor®
Phase Holographic Imaging PHI AB (“PHI” or the “Company”), a leading provider of advanced holographic imaging solutions, is pleased to update the market on the development progress of its next-generation of HoloMonitor®, which is scheduled for launch before the end of 2025. With the forthcoming launch of the new generation of HoloMonitor®, the Company will be moving into more clinically focused applications and a new, larger market segment.
Phase Holographic Imaging Signs New Distributor for Singapore and Malaysia
Phase Holographic Imaging PHI AB (“PHI” or the “Company”), is proud to announce the appointment of a new distributor, Gaia Bioscience Pte Ltd, for Singapore and Malaysia. This strategic partnership marks a significant step in PHI’s expansion into Southeast Asia, strengthening and accelerating its presence in one of the world’s most dynamic life science markets.
Interim Report 4 2024/25
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
Phase Holographic: Proposal to amend the Altium Distribution Agreement
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.
Phase Holographic: Sales summary and profit warning for the fiscal year 2024/2025
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today provides an update on the Company’s sales for the fiscal year 2024/2025. Based on the most recent developments and actual order volumes, total sales for the fiscal year are now expected to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
Phase Holographic: PHI has appointed Patrik Eschricht as new CEO
Phase Holographic Imaging PHI AB today announces that Patrik Eschricht, former CEO of PHI, will come back as CEO of the Company, effective immediately. He returns to the role he held during 2023 and most of 2024.
Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”
With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology
We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
Interim Report 3 2024/25
Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year. Gross margin continues to be strong, even slightly above planned levels (+4pp). Overall costs remain stable and as per plan, with higher administrative costs due to the capital raise offset by lower R&D expenses. The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline and company potential.